Todas as matérias desta categoria, das mais recentes às mais antigas.
AstraZeneca (NASDAQ:AZN) completed its exclusive license agreement with Dizal Pharmaceutical for worldwide rights to develop and commercialize ZEGFROVY (sunvozertinib), an oral EGFR inhibitor for patients with lung cancer.
Medtronic (NYSE:MDT) reported first quarter fiscal 2027 revenue of $9.756 billion, up 13.7% year over year on both reported and organic bases, including an estimated $570 million benefit from an additional fiscal week.
MiniMed (NASDAQ:MMED) reported first quarter fiscal 2027 net sales of $843 million, increasing 16.6% year over year on a reported basis and 15.8% organically.
Cameron Dawson, chief investment officer at NewEdge Wealth, suggests waiting for some volatility to come and create better equities buying opportunities as she says, "2Q is likely the peak in earnings growth rate."
Regis Corporation (NASDAQ:RGS) reported fourth quarter fiscal 2026 revenue of $56 million, down from $60.4 million in the prior-year quarter, while operating income reached $6.6 million.
US Army Secretary Dan Driscoll submitted his resignation to President Donald Trump and is stepping down after repeated clashes with his boss, Pete Hegseth. His resignation leaves the service without several top leaders as the conflict with Iran continues. Rachel Schilke of Bloomberg Government has more.
Wei Li, global chief investment strategist at BlackRock, says, "right now, from a total portfolio perspective," she prefers equities over credit and government bonds, however she does see "good income opportunities within fixed income that we do want to lean into."
Novartis (NYSE:NVS) reported positive Phase 3 REMODEL-1 and REMODEL-2 trial results showing remibrutinib reduced annualized relapse rates compared with teriflunomide in adults with relapsing multiple sclerosis.
NIO (NYSE:NIO) reported second quarter 2026 total revenue of RMB32.1 billion (US$4.7 billion), up 69.1% year over year, supported by higher vehicle sales across its brands.
Natera (NASDAQ:NTRA) announced the publication of new data in Blood Neoplasia showing that its Signatera circulating tumor DNA test provided prognostic and predictive information for patients with newly diagnosed and relapsed or refractory lymphoma.
Nordic Investment Bank Chief Executive Officer André Küüsvek speaks on Bloomberg Television as the Helsinki-based multilateral lender owned by the five Nordic and three Baltic countries formally added resilience, security and defense into its strategy. "We are in discussions with around 30 other potential borrowers and counterparts with a gross pipeline of about 1.2 billion worth of projects today on the table," Küüsvek says.
The premium that France pays to borrow over Germany, among the most-closely watched bond risk gauges, is near the highest since the days of Europe's sovereign debt crisis in 2012. Nerves are also spilling into France's stock and corporate debt markets, fueling underperformance versus international peers. Bloomberg's Alice Gledhill reports.
